Stocks of anti-obesity drugmakers Eli Lilly, Novo Nordisk, and Amgen faced a downturn due to concerns about a potential impact of a Robert F. Kennedy Jr.-led Department of Health and Human Services. Despite worries, experts believe the selloff presents a buying opportunity.